ASCO 2023 | How does BRAF rechallenge and retreatment impact tumor histology beyond melanoma?

Blessie Elizabeth Nelson, MBBS, DMRT, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how BRAF rechallenge and retreatment impact tumor histology beyond melanoma. Patients exposed to RAF inhibitors in the first cohort had complete or partial responses, and when rechallenged with a RAF2 inhibitor, a shorter response duration was reported. Progression-free survival (PFS) and overall survival (OS) in both the RAF1 and RAF2 cohorts were similar, and patients had a higher metastatic burden when exposed to the RAF2 inhibitor. Treatment breaks were found to have no significance on response. Combination therapies with RAF inhibitors and investigational therapies contributed to inferior outcomes. Genomic studies showed that the BRAF V600E aberration continued despite two rechallenges. Further study is required to understand these acquired mechanisms of resistance, especially after rechallenge. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.